HomeReimbursement
Content Holder

Ordering & Reimbursement

Rhophylac® is available by prescription only. It is supplied in packages containing either 1 prefilled syringe or 10 prefilled syringes.

Chart 1

*A full dose of Rhophylac® is 1500 IU; therefore, total billable units entered on the billing form should be 15.

Following is a list of authorized distributors of Rhophylac®:

  • ABO Pharmaceuticals
  • ASD Specialty
  • Anda
  • Atlantic Biologics
  • BDI Pharma
  • Cardinal SPD
  • CT International
  • FFF Enterprises
  • Health Coalition
  • Henry Schein, Inc.
  • Lifeline Pharmaceuticals LLC
  • NHS/Genesis
  • Novis Pharmaceuticals
  • Prodigy Health
  • Seacoast Medical
  • Smith Medical Partners
  • UBS/BCA/Biocare
  • US Oncology

To order, please call CSL Behring at 1-800-655-3396. For technical and medical questions about Rhophylac®, please call Medical Affairs at 1-800-504-5434.

Reimbursement

For your convenience, reimbursement codes for Rhophylac® are shown below. (Note: All codes should be verified between the provider and the payer.)

Chart 2

Please visit the CSL Behring Reimbursement Resource Center for information on insurance matters, coverage trends, patient assistance, and more.

To speak with a representative, call the Reimbursement Answerline at 1-800-676-4266 Monday through Friday from 8 a.m. to 5 p.m. ET. Find out about:

  • Claim processing reviews
  • Appeals
  • Insurance investigations into product coverage
  • Prior approvals for therapies authorization
Chart 3 Chart 4 Chart 5

*An intravenous push is defined as: a) an injection in which the healthcare professional who administers the substance/drug is continuously present to administer the injection and observe the patient,or b) an infusion of 15 minutes or less.

This resource provides information from a complex and evolving medical coding system. The treating physician is solely responsible for diagnosis coding and determination of the appropriate ICD-9-CM codes that describe the patient’s condition and are supported by the medical record. All codes listed in this guide are for informational purposes and are not an exhaustive list. The CPT, HCPS, and ICD-9-CM codes provided are based on AMA or CMS guidelines. The billing party is solely responsible for coding of services (eg, CPT coding). Because government and other third-party payor coding requirements change periodically, please verify current coding requirements directly with the payor being billed.
IMPORTANT SAFETY INFORMATION

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in:

  • Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
  • Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isoimmunization, Rhophylac® can be administered IM or IV.

Rhophylac® is indicated to raise platelet counts in Rho(D)-positive, non-splenectomized adult patients with chronic immune thrombocytopenic purpura (ITP). For the treatment of ITP, Rhophylac® must be administered IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Suppression of Rh Isoimmunization: For postpartum use following an Rh-incompatible pregnancy, Rhophylac® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac® are nausea, dizziness, headache, injection-site pain, and malaise.

Immune Thrombocytopenic Purpura: The most serious adverse reactions in patients receiving Rho(D) immune globulin have been observed in the treatment of ITP. ITP patients being treated with Rhophylac® should be monitored for signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and hemoglobinuria. Potentially serious complications of intravascular hemolysis include clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation, and death.

The most common adverse reactions observed in the treatment of ITP are chills, pyrexia/increased body temperature, and headache. Mild extravascular hemolysis has also been observed. In patients with preexisting anemia, weigh the benefits of Rhophylac® against the potential risk of increasing the severity of the anemia.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.